What do you want to know about Ozempic and other weight-loss drugs in Canada? Send us your questions

Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy in London in March, 2024.Hollie Adams/Reuters

The Q&A is happening on Feb. 27 from 11 a.m. to noon ET. Here’s how to submit a question:

The Q&A is taking place in the comment section of this article. Click here to head there and leave a question.
You can also submit a question for our reporters by sending an e-mail to audience@globeandmail.com, or filling out the submission box at the bottom of this article.
To see the answers to your questions, be sure to bookmark this page and head back on Feb. 27 at 11 a.m. ET to read our responses.

This year, Canada could become the first country in the West, and possibly the first in the world, to get generic — and much cheaper —copies of semaglutide, the culturally ubiquitous Type 2 diabetes drug best known as Ozempic.

Semaglutide is also sold as Wegovy, a higher-dose version approved specifically for weight loss, as well as for cardiovascular and metabolic liver disease in Canada.

How will cheaper versions of Ozempic tip the scales?

Much easier to access at a lower price point, generic Ozempic could prove to be a godsend for Canadians who are obese and in ill health, but potential side effects and an already-weight-obsessed online culture have others worried.

Meanwhile, companies are descending on Canada to be the first to capitalize on this new market.

On Feb. 27 from 11 a.m. ET to noon, reporters Kelly Grant and Chris Hannay will be answering reader questions on the rise of Ozempic and similar drugs in Canada, what experts are saying about the health risks and benefits and how it will change the pharmaceutical industry in the country.

Why is generic Ozempic coming to Canada before anywhere else? How does this play into the online obsession with weight loss? How will it change the health landscape in Canada? Submit your questions now.